Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

Market Cap	17.01B +7.6%
Revenue (ttm)	6.10B +3.8%
Net Income	388.91M -46.0%
EPS	0.27 -46.0%
Shares Out	n/a
PE Ratio	43.74
Forward PE	n/a
Dividend	0.27 (5.51%)
Ex-Dividend Date	May 26, 2025

Volume	324,500
Average Volume	549,850
Open	4.930
Previous Close	4.930
Day's Range	4.910 - 4.970
52-Week Range	4.240 - 7.260
Beta	0.45
RSI	44.06
Earnings Date	Mar 30, 2026

About HKG:9989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 1,926
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9989

Financial Performance

In 2025, HKG:9989's revenue was 5.48 billion, an increase of 4.18% compared to the previous year's 5.26 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial numbers in CNY